Position 4 analogues of r-alanine in the peptide subunit of uridine 5'-diphosphate-N-acetylmuramyl-Alal-DGlu2-Lys3-DAla4-DAla5 have a significant inhibitory effect on penicillin-sensitive peptidoglycan synthesis in Gaffkya homari (C. V. Carpenter, S. Goyer, and F. C. Neuhaus, 1976) . The specificity profile of this in vitro system has been used as a basis for designing analogues with potential antibacterial activity. To circumvent the specificity determinants exerted by Dalanine:D-alanine ligase (adenosine 5'-diphosphate), attention was directed to DD-dipeptides of the type z)-alanyl-analogue-i-alanine as a method for incorporating analogues into position 4 of the peptide subunit in vivo. Of the three dipeptides, DAbu-DAla, DNva-DAla, and DVal-DAla, only DNva-DAla (5 x 10-4 M) inhibited the growth of Escherichia coli W in the presence of 5 x 10-6 M Dcycloserine. This concentration of D-cycloserine did not inhibit growth, but it potentiated the bactericidal activity of the dipeptide. The lack of antibacterial activity observed with DAbu-DAla and DVal-DAla was correlated with the poor ability of these dipeptides to be taken up via the dipeptide transport system of this organism. Prevention of lysis induced by DNva-DAla plus D-cycloserine by certain dipeptides and not by others supported this correlation. It is proposed that the r)-norvalyl residue of the dipeptide is incorporated in vivo into position 4 of the peptide subunit of peptidoglycan, and that this subunit is not an effective substrate in the reaction(s) catalyzed by the penicillin-susceptible enzyme(s) of cross-linked peptidoglycan synthesis.
DD-dipeptides of the type z)-alanyl-analogue-i-alanine as a method for incorporating analogues into position 4 of the peptide subunit in vivo. Of the three dipeptides, DAbu-DAla, DNva-DAla, and DVal-DAla, only DNva-DAla (5 x 10-4 M) inhibited the growth of Escherichia coli W in the presence of 5 x 10-6 M Dcycloserine. This concentration of D-cycloserine did not inhibit growth, but it potentiated the bactericidal activity of the dipeptide. The lack of antibacterial activity observed with DAbu-DAla and DVal-DAla was correlated with the poor ability of these dipeptides to be taken up via the dipeptide transport system of this organism. Prevention of lysis induced by DNva-DAla plus D-cycloserine by certain dipeptides and not by others supported this correlation. It is proposed that the r)-norvalyl residue of the dipeptide is incorporated in vivo into position 4 of the peptide subunit of peptidoglycan, and that this subunit is not an effective substrate in the reaction(s) catalyzed by the penicillin-susceptible enzyme(s) of cross-linked peptidoglycan synthesis.
The design of potential analogues of D-alanine that inhibit the assembly of cross-linked, functional peptidoglycan requires that they be incorporated into a precursor where they can exert their effect. Inhibition ofthe cross-linking reaction by such analogues would lead to the synthesis of a polymer that is unable to function in normal wall formation. Amino acid residues 4 and 5 ofthe peptide moiety ofpeptidoglycan play an important role in cross-linking. Analogues of D-alanine in position 4 have a significant in vitro inhibitory effect on penicillin-sensitive peptidoglycan synthesis in Gaffkya homari (1) . For example, if D-alanine in this position is replaced by r-norvaline, less than 2% of the in vitro synthetic activity is observed. Thus, incorporation of analogues ofDalanine into position 4 of the peptide moiety may provide a useful tool for controlling bacterial growth.
Because of the specificity determinants of Dalanine:D-alanine ligase, it is not possible for the cell to utilize D-norvaline for the synthesis of D-norvalyl-i-alanine (DNva-DAla) (8, 9) . However, since uridine 5'-diphosphate-N-acetylmuramyl (UDP-MurNAc)-Ala-DGlu-Lys: DAla-DAla ligase will utilize DNva-DAla, it is possible to incorporate the analogue into position 4 via the dipeptide (11) . The potential antibacterial action of this analogue in this position will require that the dipeptide, DNvaDAla, be transported by the cell.
The transport of dipeptides by Escherichia coli is catalyzed by a dipeptide system that has a high specificity for amino acid residues of the L configuration (2, 5, 6, 13, 14) . However, prevention of lysis by D-cycloserine with DAla-DAla implies that this dipeptide is also taken up from the medium (P. Chambers, J. Bing, J. Lynch, F. C. Neuhaus, and R. W. Brockman, Bacteriol. Proc., p. 119, 1963). Kessel and Lubin (5) observed that DAla-DAla is an inhibitor of GlyGly transport. These results suggest that DAlaDAla is transported via the dipeptide system that accumulates Gly-Gly, and that this system may play a role in the uptake of the dipeptide analogues of DAla-DAla.
The purpose of these experiments is to exam-ine the effect of analogues of DAla-DAla, with emphasis on DNva-DAla, on the growth of E. coli W. (11) .
Strains and medium. E. coli W ATCC 9637 was maintained in vacuo at -20°C. The minimal medium for growing these strains was: 0.1% NH4Cl, 0.3% NaH2PO4 H20, 0.6% K2HPO4, 0.02% MgSO4, 0.05% NaCl, and 0.4% glucose. Minimal medium minus glucose will be designated buffer A. The cultures for the growth experiments (10 ml) were grown at 37°C on a New Brunswick Syrotory shaker (setting, 80). Bacterial growth was monitored turbidimetrically by measuring the absorbance of the culture at 650 nm in a spectrophotometer (Bausch and Lomb Spectronic 20) against medium.
Measurement of dipeptide uptake. For transport experiments, the bacteria were grown in 500-ml cultures to a turbidity of 0.4 in minimal medium containing 0.4% glucose. Chloramphenicol was then added to the culture to make a concentration of 200 Fg/ml; the culture was maintained for an additional 30 min at 37°C. The cells were harvested, washed, and resuspended in buffer A (4°C) containing 200 Lg of chloramphenicol per ml to give 200 mg (wet weight) per ml. The cell suspension was maintained at 4°C until used (<4 h).
The procedure for measuring the uptake of labeled dipeptides by nongrowing cells was similar to the method described by Wargel et al. (16) . A portion (6 x 10. cells in 150 Mul) of the cell suspension was added to 750 Ml of minimal growth medium (glucose) that contained chloramphenicol (200 MLgI ml), and the suspension was maintained at the accumulation temperature for 5 min. From this suspension, 600 Ml was added to 400 Ml of medium (chloramphenicol) containing the labeled dipeptide (5 x 10-5 M). Samples (200 Ml) were removed at the desired time, and the cells were collected on a damp 0.45-pm-pore-size membrane filter. The cells were washed with buffer A (10 ml) at 25°C, and the damp membrane filter and cells were dissolved in 1 ml of ethyl acetate. The amount of radioactivity was determined according to the procedure described by Patterson and Greene (12) . (Fig. 2) .
The specificity of growth inhibition is summarized in Table 1 . Of the dipeptides tested, only DNva-DAla inhibits bacterial growth at 5 X 10-4 M in the presence of 5 x 10-M Dcycloserine. When equimolar concentrations of n-norvaline and D-alanine (5 x 10-4 M) replace DNva-DAla, growth inhibition was not observed. Thus, DNva-DAla would appear to exert a specific inhibition that results in lysis of the culture.
Prevention of D-cycloserine-induced lysis. Growth of E. coli W in concentrations of Dcycloserine higher than 7.5 x 10-f M results in lysis of the bacterial culture. Chambers et al. (1963) observed that this inhibition is prevented by DAla-DAla. These results suggested that E. coli could utilize this dipeptide for the synthesis of UDP-MurNAc-pentapeptide. Prevention of lysis by a dipeptide would appear to be a good indication of those dipeptides that are transported and utilized for the synthesis of functional peptidoglycan. Of MurNAc-pentapeptide synthesis, or are utilized for the synthesis of nonfunctional peptidoglycan. Prevention of DNva-DAla-induced lysis. The addition of either DAla-DAla (Fig. 3A) or nalanine (Fig. 3B) antagonizes the effect exerted by DNva-DAla. Prevention of lysis with DD-dipeptides that are analogues of DAla-DAla is summarized in Table 3 . Except for DVal-DAla and DAla-DVal, each of the peptides has some ability to prevent DNva-DAla-induced lysis when tested at equimolar concentrations. An interesting feature of this experiment is that DAla-DNva prevents the lytic action induced by DNva-DAla. In Table 3 (experiment 2), additional specificity studies reveal that the prevention is not restricted to dipeptides of the DDconfiguration. Gly-Gly, LAla-LAla, and LNvaIr-
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LAla have some ability to prevent the inhibitory activity exerted by DNva-DAla. Two interpretations ofthese data may be considered. The antagonizing dipeptide either inhibits the uptake of DNva-DAla or it effectively competes with DNva-DAla for addition to UDP-MurNActripeptide in the reaction catalyzed by UDPMurNAc-tripeptide:DAla-DAla ligase, resulting in a functional subunit. However, since specificity studies with this enzyme eliminate LLdipeptides as substrates for this enzyme (4, 11) , it would appear that these dipeptides inhibit the uptake of DNva-DAla. 
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Transport of DNva-DAla. An analysis of the transport system that is responsible for the accumulation of DAla-DAla may provide a basis for interpreting the specificity studies described above. E. coli has a specific transport system for dipeptides (2, 6, 13, 14) . Payne (13) concludes that dipeptide transport "appears to have a stereospecific requirement for L-residues." However, Kessel and Lubin (5) observed that DAla-DAla is an inhibitor of Gly-Gly uptake. These results suggest that DAla-DAla may be accumulated via the dipeptide transport system. The uptake of DAla-DAla byE. coli KMBL-146 has been briefly described (7) . To establish the role of the dipeptide transport system for the accumulation of these DD-dipeptides, a series ofexperiments was initiated with both DAla-DAla uptake and Gly-Gly uptake. On the basis of these results, it would appear that Gly-Gly and DAla-DAla are transported by a common system, a result that is implied from the inhibition data presented by Kessel and Lubin (5) .
Each of the analogue dipeptides has been (Table 4 ). It will be assumed that dipeptides which inhibit the uptake of either labeled dipeptide are also substrates for the dipeptide transport system. This assumption is necessary since labeled analogues of DAla-DAla are not readily available.
As summarized in Table 4 , DNva-DAla, DAlaDAbu, and DAla-DNva are relatively better in-
Ala uptake than are DAla-DVal, DVal-DAla, and DAbu-DAla. With ["4C]Gly-["C]Gly as the labeled dipeptide, DAla-nAla, DNva-DAla, DAla-DNva, and DAlaDAbu are better inhibitors of dipeptide uptake than are DVal-DAla, DAla-DVal, and DAbuDAla. The similarity in inhibition profiles indicates that DAla-DAla, DNva-DAla, DAla-DNva, and DAla-DAbu are transported via the dipeptide transport system described by Kessel and Lubin (5).
DISCUSSION
The successful incorporation of a D-alanine analogue into position 4 of the peptide subunit of peptidoglycan is dependent on the specificity determinants of a variety of enzyme and transport systems. Each of these exerts its discrimination against the potential analogue. In our studies of n-alanine:-alanine ligase, it was evident that this enzyme has a high degree of specificity for the N-terminal residue, the precursor of the D-alanine residue in position 4 of the peptide subunit (8, 9) . To circumvent these specificity determinants, attention was directed to DD-dipeptides that have the N-terminal D-alanine analogue. Specificity studies with UDP-MurNAc-Ala-DGlu-Lys:DAla-DAla ligase indicated that changes in the N-terminal residue of the dipeptide, e.g., ri-a-amino-n-butyric acid and n-norvaline, would not affect the activity catalyzed by this enzyme (11) . Thus, the use of DD-dipeptides of the type D-alanyl-analogueDAla was considered as a potential method for incorporating an analogue into position 4 of the peptide subunit in vivo.
Incorporation of either D-a-amino-n-butyric acid, D-norvaline, or D-valine into residue 4 of the peptide subunit relative to incorporation into residue 5 significantly inhibits the in vitro synthesis of penicillin-sensitive peptidoglycan in membrane wall preparations from G. homari (1). Thus, three dipeptides, DAbu-DAla, DNva-DAla, and DVal-DAla have been considered for potential antibacterial activity. Of the three, only DNva-DAla has the ability to inhibit growth under the conditions tested. To potentiate the activity, a concentration of D-cycloserine that does not inhibit growth was added to the medium. It was assumed that this concentration was sufficient to limit the amount of DAla-DAla synthesized in the alanine branch of peptidoglycan synthesis but would allow the same rate of growth as in the control. The lack of antibacterial activity observed with DAbuDAla and DVal-DAla can be correlated with the relatively poorer ability of these dipeptides to inhibit the uptake of DAla-DAla and Gly-Gly. Thus, it is presumed that these analogues are not transported via the dipeptide system to a significant extent under the conditions tested. On the other hand, DNva-DAla, which inhibits the uptake of DAla-DAla and Gly-Gly, does have significant antibacterial activity. Our data suggest that this dipeptide is transported as effectively as DAla-DAla, DAla-DAbu, and DAla-DNva.
Prevention of D-cycloserine-induced lysis by DD-dipeptides provides an independent method of testing for those dipeptides that are transported and utilized for the synthesis of functional peptidoglycan. In addition to DAla-DAla, DAla-DAbu and DAla-DNva prevent the lysis induced by D-cycloserine. These results imply that the three dipeptides satisfy the dipeptide requirement for UDP-MurNAc-pentapeptide synthesis. Since DAla-DVal lacks the ability to prevent lysis induced by D-cycloserine, it is presumed that DAla-DVal is not taken up. Although DNva-DAla appears to be transported, no prevention of D-cycloserine-induced lysis is observed. It is presumed that the defective peptidoglycan with residue 4 replaced by D-norvaline is synthesized and that this glycan does not participate in cross-linked peptidoglycan synthesis (1).
Prevention of DNva-DAla-induced lysis by DDdipeptides provides an indication of those dipeptides that effectively compete with DAlaDAla for transport into the bacterium. In addition, Gly-Gly, lAla-LAla, and LNva-LAla were effective in preventing the action ofDNva-DAla. The specificity of the dipeptide transport system suggests that uA-dipeptides and Gly-Gly will compete effectively with DNva-DAla and thus prevent the uptake of this DD-dipeptide. DAla-DNva prevents the inhibitory action of DNva-DAla. On the other hand, DAla-DVal cannot prevent the action of DNva-DAla because it does not compete for the transport system. Thus, the interpretation of the growth experiments relies on the definition of the specificity profile of the transport system. The antibacterial activity of the DD-dipeptide not only reflects the specificity determinants of the relevant enzyme systems, but it also must reflect the specificity determinants exerted by the transport system.
Analogues of DAla-DAla with C-terminal substituents have been synthesized and tested for antibacterial activity (3, 15) . None of these compounds showed significant antibacterial activity. On the basis of our specificity studies, it is doubtful that analogues with changes in the C-terminal residue would have been ligated to UDP-MurNAc-tripeptide. Alternatively, if VOL. 11, 1977 on October 16, 2017 by guest http://aac.asm.org/ Downloaded from they had been added to the -tripeptide, the analogue would have been incorporated into position 5 rather than into position 4. Incorporation of an analogue into position 5 does not have a major effect on the cross-linked peptidoglycan synthesis relative to incorporation of an analogue into position 4 in G. homari (1) .
